Breakthrough T1D is partnering with Pfizer’s Centers for Therapeutic Innovation (CTI) to support the development and translation of promising diabetes research. The collaboration will initially focus on co-funding projects in the fields of immune tolerance, diabetic nephropathy, and beta cell health.

“CTI’s business model is to build novel partnerships that combine our drug discovery expertise with external innovation, and we’ve found a great partner in Breakthrough T1D,” says Dr. Anthony J. Coyle, chief scientific offer at Pfizer’s CTI. “Combining Pfizer’s scientific resources with Breakthrough T1D’s deep knowledge of type 1 diabetes and excellent network of investigators, I believe we will be well-positioned to pursue better, more targeted medicines for diabetes patients.”